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Oncometabolite
InﬂammationAbnormal accumulation of oncometabolite fumarate and succinate is associatedwith inhibition ofmitochondrial
function and carcinogenesis. By competing with α-ketoglutarate, oncometabolites also activate hypoxia induc-
ible factors (HIFs), which makes oncometabolite mimetics broadly utilised in hypoxia research. We found that
dimethyloxalylglycine (DMOG), a synthetic analogue of α-ketoglutarate, commonly used to induce HIF signal-
ling, inhibits O2 consumption in cancer cell lines HCT116 and PC12, well before activation of HIF pathways. A
rapid suppression of cellular respiration was accompanied by a decrease in histone H4 lysine 16 acetylation
and not abolished by double knockdown of HIF-1α and HIF-2α. In agreement with this, production of NADH
and state 3 respiration in isolated mitochondria were down-regulated by the de-esteriﬁed DMOG derivative,
N-oxalylglycine. Exploring the roles of DMOG as a putative inhibitor of glutamine/α-ketoglutarate metabolic
axis, we found that the observed suppression of OxPhos and compensatory activation of glycolytic ATP ﬂux
make cancer cells vulnerable to combined treatment with DMOG and inhibitors of glycolysis. On the other
hand, DMOG treatment impairs deep cell deoxygenation in 3D tissue culture models, demonstrating a potential
to relieve functional stress imposed by deep hypoxia on tumour, ischemic or inﬂamed tissues. Indeed, using a
murine model of colitis, we found that O2 availability in the inﬂamed colon tissue rapidly increased after applica-
tion of DMOG, which could contribute to the known therapeutic effect of this compound. Overall, our results
provide new insights into the relationship between mitochondrial function, O2 availability, metabolic
reprogramming and associated diseases.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cellular responses to reduced O2 availability, a common stressful
condition for aerobic organisms, are regulated in a complex fashion
and depend on the degree and duration of hypoxia, nutrient supply,
metabolic activity and sensitivity of the tissue. Cells utilise multiplectivated protein kinase; DMSO,
rotein; EPAS1, endothelial PAS
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g, College Road, Cork, Ireland.regulatorymechanisms directed to their survival and restoration of nor-
mal O2 supply. Hypoxiamodulates cellular function directly through ac-
tivity of O2-dependent enzymes (oxidases, oxygenases, including
hydroxylases), or indirectly through redox state, AMP/ATP ratio, levels
of ROS and metabolic intermediates which can be sensed and get in-
volved in the different regulatory cascades [1,2]. For one of the major
pathways – HIF signalling – both direct (i.e., trough hydroxylation of
proline residues by PHD and FIH enzymes) and indirect (e.g., via chang-
es in ROS, Krebs cycle metabolites and Fe2+ levels) regulations have
been demonstrated [3].
Since their discovery [4–7], HIFs attracted much attention as key
transcriptional regulators of responses to hypoxia at cellular and sys-
temic levels, protecting tissues from ischemic damage and maintaining
normal O2 supply via EPO production and angiogenesis [8–10]. The in-
volvement of HIFs inmalignant transformation and tumour progression
is also important [11]. Stabilised in an O2-dependent and independent
manner, HIF-1 and HIF-2 were shown to rescue hypoxic tumours from
death through bioenergetic adaptation to conditions life-threatening
for normal tissues [12]. On the other hand, anti-cancer effects of HIFs
were also demonstrated [13].
Due to the antagonistic effects of HIFs [3,14], development of drugs
speciﬁcallymodulating HIF signalling in different tissues and conditions
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[15], similar to the oncometabolites fumarate, succinate and 2-
hydroxyglutarate [16], most of the synthetic compounds also affect
other pathways. Being of no exception, dimethyloxalylglycine (DMOG),
a competitive inhibitor of PHD used for HIF stabilisation in cell and an-
imal models, also demonstrates multiple pharmacological effects.
Invented as a dimethyl ester of N-oxalylglycine (NOG), an amide ana-
logue ofα-KG [17,18], DMOGeasily permeates the cells, where it is con-
verted into NOG by cellular carboxylesterases and accumulates [18,19].
As a PHD inhibitor, DMOG activates HIF-1 and NF-κB, playing a protec-
tive role in experimental model of colitis and diarrhoea [20,21], sup-
presses induced TNF-α expression [22] and abrogates TNF-α-induced
intestinal epithelial damage [23]. On the other hand, DMOGwas also re-
ported to inhibit JHDM histone demethylases in 293T cells [24], similar
to NOG [24–26]. Recently, DMOG was shown to activate AMPK signal-
ling [27], which orchestrates global metabolic adaptation of cells to en-
ergy crisis and oxidative stress [28]. Similarly to HIF, the AMPK pathway
increases glycolytic ﬂux and triggers energy preservation programmes
[29,30]. But in contrast to the inhibition of mitochondrial function and
biogenesis by HIF [8,31], AMPK up-regulates growth and activity of mi-
tochondria [32,33], acting primarily through PGC-1α pathway [34–36].
Prolonged incubation with DMOG was seen to inhibit mitochondrial
function and activate glycolysis in cardiomyocytes, acting via PHD/
HIF-dependent (reduced respiration) and HIF-independent (reduced
ATP consumption) mechanisms [37,38]. A similar PHD-driven effect of
DMOG was demonstrated in cancer cell lines [39].
Although DMOG inhibits a broad range of α-KG-dependent hydrox-
ylases [18,40–42], its direct inhibitory effect on mitochondrial function
and cellular respiration has never been addressed.However, by compet-
itive inhibition of themitochondrialα-KGdehydrogenase, isocitrate de-
hydrogenase and other enzymes DMOG potentially can change cell
metabolism much faster than via activation of HIF signalling. Therefore
we hypothesised that many metabolic effects of DMOG may be PHD-
and HIF-independent, and directly attributed to the inhibition of respi-
ration and mitochondrial ATP ﬂux. Our results show a rapid inhibitory
effect of DMOG on mitochondrial respiration and ATP production in
cancer cells coupled with compensatory increase in glycolysis, which
develops in minutes and clearly surpasses PHD-dependent processes
regulated by HIFs. Decreased respiration leads to a concomitant eleva-
tion of O2 in colon cancer cell spheroids and in inﬂamed mouse colon
tissue, thus ameliorating energy stress imposed by hypoxia.
2. Materials and methods
2.1. Materials
O2-sensitive probes MitoXpress®-Xtra [43], MitoXpress®-Intra
NanO2 [44], Pt-Glc [45] and pH-sensitive probe pH-Xtra [46] were
from Luxcel Biosciences (Cork, Ireland). Cytosolic pH probe BCECF AM,
Lipofectamine® 2000 and Opti-MEM I were from Invitrogen Life Tech-
nologies (Carlsbad, CA). ECL Prime Western blotting reagent was from
GE Healthcare Life Sciences (Waukesha, WI), pre-made acrylamide
gels, running and transfer buffers were from GeneScript (Piscataway,
NJ), BCA™ Protein Assay kit, RIPA buffer and pre-stained protein ladder
were from Thermo Scientiﬁc (Rockford, Ill). PhosStop Phosphatase In-
hibitor and Complete Protease Inhibitor Cocktail Tablets were from
Roche (Ireland). The plasmid encoding mitochondria-targeted GFP-
based pH sensor mtAlpHi was kindly provided by Prof. T. Pozzan
(Padua, Italy). CellTiter-Glo® ATP Assay, RNA isolation kit
ImProm-II™ and Reverse Transcription System were from Promega
(Madison, WI). Immobilon PVDF membrane, DMOG, STF-31 and
FM19G11 were from Merck Millipore (Billerica, MA). Stainless
Steel Minuten Pins (0.2 mm) were from Fine Science Tools (Foster
City, CA). Sylgard® 184 silicon elastomer kit was from Dow Corning
(Midland, MI). Mineral oil (type 37) was from Cargille Laboratories
(Cedar Grove, NJ). NOG was from Echelon Biosciences Inc. (SaltLake City, UT). McCoy's 5A, Dulbecco's Modiﬁed Eagle's (DMEM)
and Roswell Park Memorial Institute (RPMI) media, Krebs buffer,
nerve growth factor (NGF), lonidamine, α-ketoglutarate dehydro-
genase from porcine heart (α-KGDH, EC number 1.2.4.2), ß-nico-
tinamide adenine dinucleotide (NAD+), coenzyme A (CoA), α-KG,
L-cysteine, esiRNA targeting human HIF1A, human EPAS1 (HIF2A)
and EGFP (negative control), collagen IV and other reagents were
from Sigma-Aldrich. Primers and antibodies used are described in
Supplemental Tables 1 and 2.
2.2. Animals and dextran sodium sulfate (DSS)-induced colitis
Animal experiments were conducted in accordance with EU Direc-
tive 86/609/EEC and approved by the Animal Experimentation Ethics
Committee of University College Cork. Male mice, C57BL/6OlaHsD
(Harlan, UK) aged 10–12 weeks, were housed in groups of ﬁve per
cage on a 12 h light/dark cycle. Mice were given 3% DSS (45 kDa; TdB
Consultancy, Uppsala, Sweden, prepared fresh daily) in their drinking
water for 4 days as described previously [47]. In the control group ani-
mals received water. Disease progression was assessed by monitoring
bodyweight loss, stool consistency and fur texture/posture as previous-
ly described [48].
2.3. Tissue culture, composition of the media and experimental conditions
Human colon carcinoma HCT116 and rat pheochromocytoma PC12
cells were from American Tissue Culture Collections (ATCC, Manassas,
VA). HCT116 cells weremaintained in adherent state inMcCoy's 5Ame-
dium supplemented with 10mMHEPES (pH 7.2), 2 mm L-Gln, 10% foe-
tal bovine serum (FBS), 100 U/mL penicillin/100 μg/mL streptomycin
(P/S) in humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C.
For iO2, OCR and ATP measurement, cells were seeded in a
growing medium at 2–4 × 104 cells/well on 96-well plates (Greiner
Bio One, Frickenhausen, Germany) coated with 0.01% collagen IV. For
protein and RNA isolation 4 × 105 cells/well were seeded on 12-well
plates (Corning Life Sciences, NY) coated similarly. For iO2 imaging
cells were seeded at 1.5–2 × 104 cells per ~1 cm2 on glass bottom
mini-dishes (MatTek, Ashland, MA) coated with a mixture of collagen
IV (0.007%) and PDL (0.003%). In all cases, cellswere grown for 1–2 days
prior to analysis. For NADH analysis 5 × 105 cells per onewell of 96-well
platewere used in suspension. For O2 imaging in spheroids, 2 × 103 cells
were placed in the wells of Lipidure-Coat U-bottom 96-well plate (AMS
Biotechnology, UK) in 200 mL of the medium containing 5 μg/mL
NanO2 probe. Spheroids were grown for 3 days; the probe was diluted
to 3.5 μg/mL and ~2 μg/mL after 24 h and 48 h of the incubation. After
that spheroids were gently transferred to the MatTek dishes coated
with collagen/PDL and left for 3–4 h to attach to the surface of dishes.
Medium was replaced with 3 mL of fresh DMEM, supplemented with
2 mM glutamine, 1 mM pyruvate and either glucose or galactose
(10 mM); iO2 was imaged as described below for mouse colon tissue.
Suspension PC12 cells were maintained in the same conditions in
RPMI 1640 medium supplemented with HEPES, L-Gln, 10% horse
serum (HS), 5% FBS and P/S. In all experiments, cells were differentiated
for 3–4 days in RPMI supplemented with HEPES, L-Gln, 1% HS, P/S, and
100 ng/mL NGF, as described [49]. For iO2/ATP measurement and
protein/mRNA isolation, cells were seeded at 5 × 104 cells/well on 96-
well plates and 5 × 105 cells/well on 12-well plates (respectively), coat-
ed with collagen IV (0.01%).
Assay media for acidiﬁcation rate, iO2 and ATP analyses were pre-
pared from plain DMEM (Sigma, Cat. No 5030) reconstituted in
deionised water, ﬁlter-sterilised and supplemented with 2 mM L-Gln,
1 mM pyruvate, 10 mM glucose or galactose and 100 nM NGF (only
for PC12 cells), no serum. All media, except for medium acidiﬁcation
measurements, contained 20 mM HEPES, pH 7.2. Prior to the iO2 and
ATP experiments, growth medium was replaced with assay media,
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powder as fresh 100× aqueous stock solution andused at 1mMconcen-
tration (unless speciﬁed otherwise). Other treatments are described in
results section.2.4. O2 consumption rate (OCR) assay
Cellular OCR was measured using a well-established phosphores-
cence quenching technique using MitoXpress®-Xtra probe and trans-
parent 96-well plates on Victor 2 TR-F plate reader (PerkinElmer Life
Sciences, Waltham, MA) [43]. Brieﬂy, measurements were conducted
in 100 μL of DMEM supplementedwith 200 nMprobe and DMOG at dif-
ferent concentrations (0–2 mM), each sample sealed with mineral oil.
Two intensity readings (340 nm excitation and 642 nm emission)
taken repeatedly at delay times of 30 and 70 μs and gate time 100 μs
were converted into phosphorescence lifetime (τ) values as follows:
τ= (t2− t1) / ln(F1 / F2), where F1, F2 are the TR-F intensity signals at
delay times t1 and t2. Then OCR for each DMOG concentration was cal-
culated as O2 consumed by cells in 1 min per 1 mg of total soluble
protein.2.5. Measurement of intracellular O2
Measurement of iO2 was performed using the phosphorescence
quenching method [50] on Victor 2 plate reader (NanO2 probe) and
confocal microscope (NanO2 and Pt-Glc probes) [45].
Plate reader experiments were conducted as described in [44] in
200 μL of DMEM. Phosphorescence lifetime values were calculated and
converted into iO2. For cell stimulation, plates were quickly withdrawn,
FCCP (1.5 μM) or EGTA (5 mM) were added (20 μL of 10× stock solu-
tion) and monitoring was resumed. For the experiments at 8% and 5%
O2, the volume of assay medium was adjusted to 300 μL and the plate
reader was placed in a hypoxia chamber (Coy Laboratory Products,
Grass Lake, MI) set at 8% or 5% O2; each sample well was measured re-
petitively over 4 h. Stimulation of cells with DMOG or antimycin A
(AntA) was performed as shown in results section. iO2 concentrations
and deoxygenation rates were calculated as described [44].
For ex vivo colon tissue staining, mice with DSS-induced colitis and
controls were sacriﬁced, the distal colons were dissected and stretched
using Minuten Pins on the surface of Sylgard polymerised in 3.5 cm2
Petri dishes according to the manufacturer's protocol. The tissue was
washedwith Krebs buffer, coveredwith 2mL of Krebs buffer containing
2% BSA and Pt-Glc probe (20 μM) and incubated for 3 h at 37 °C in a CO2
incubator. After washing, fresh Krebs buffer (3 mL) supplemented with
2 mM L-glutamine and 0.5 μM nifedipine (to prevent muscle contrac-
tion) was added and samples were imaged on a confocal PLIM system
described in [45]. The system was based on an upright ﬂuorescent mi-
croscope AxioExaminer Z1 with 20×/1.0 W-Plan-Apochromat water
immersion objective (Carl Zeiss), DCS-120 confocal scanner, TCSPC
module (Becker & Hickl) and R10467U-40 photon counting detector
(Hamamatsu Photonics K.K.). The probe was excited with a 405 nm
picosecond diode laser BDL-SMC (Becker &Hickl) and emissionwas col-
lected at 635–675 nm in PLIM mode using SPCM software (Becker &
Hickl). Confocal images were collected in 10–20 optical planes with
5 μm steps, phosphorescence lifetimes were calculated from mono-
exponential decay ﬁts in SPCImage software (Becker & Hickl). 2D
256 × 256 pixel matrices of lifetime data for each measurement were
extracted to Excel and converted into O2 concentration using calibration
equation (see ‘Calibration of Pt-Glc probe’). O2 levels in randomly select-
ed ROIs and lifetime distribution histograms were analysed for individ-
ual planes.
3D images were reconstructed using ImageJ and processed in Adobe
Photoshop and Illustrator programs. DIC images were recorded with a
D5100 digital camera (Nikon) connected to the microscope.2.6. Calibration of Pt-Glc probe
To calibrate Pt-Glc for O2 imaging analysis, colon tissue was loaded
with the probe as above, washed in Krebs buffer and stretched on the
surface of Sylgard polymerised in 24-well plate (Corning). Tissue respi-
ration was inhibited by double treatment with AntA (10 μM) and NaN3
(0.1%) for 2 h. Plate with tissue samples wasmeasured continuously on
Victor 2 plate reader placed in a hypoxia chamber, as described for
NanO2 probe. Pt-Glc probe phosphorescence wasmeasured at different
atmospheric O2 levels (17, 12, 6, 3, 1.5 and 0%). A complete deoxygen-
ation was achieved by addition of sodium sulﬁte [45]. For each O2
level τ was calculated, and then the following equation was obtained:
O2 (μM) = 10 × e(39.27 − τ) / 5.08.2.7. Isolation of mitochondria and measurement of mitochondrial OCR
To analyse direct effects of DMOG and NOG on mitochondrial respi-
ration, mitochondria were isolated from rat liver as previously de-
scribed [53] with modiﬁcations. Male Sprague–Dawley rats (Harlan,
UK) aged 3–4 months, were housed in groups of two per cage on a
12 h light/dark cycle. Rats were culled by a standard cervical dislocation
(EU Directive 86/609/EEC), and liver was excised. Approximately 3 g of
freshly dissected liver tissue was minced by scissors, washed several
times in isolation buffer I (210 mM mannitol, 70 mM sucrose, 5 mM
HEPES, 1 mM EGTA, and 0.25% fatty acids free BSA, pH 7.4) and
homogenised in 15 mL of isolation buffer I using Sartorius Potter S
homogeniser driven by handle drill on low speed. Homogenate was
clariﬁed by centrifugation at 700 g for 10 min at 4 °C. The supernatant
was ﬁltered through the cheesecloth and centrifuged at 14,000 g for
10 min at 4 °C. The pellet containing mitochondria was washed with
20 mL of isolation buffer I, then with 20 mL of isolation buffer II
(210 mM mannitol, 70 mM sucrose, 10 mM MgCl2, 5 mM K2HPO4,
10 mM MOPS and 1 mM EGTA, pH 7.4) and precipitated at 10,000 g
for 10min at 4 °C. The ﬁnal pellet was re-suspended in 2mL of isolation
buffer II and kept on ice. All procedureswere performed on ice using ice-
cold buffer solutions and pre-chilled instruments. Mitochondrial pro-
tein concentration was determined by BCA protein assay kit.
Mitochondrial OCR assay was performed using MitoXpress®-Xtra
probe (100 nM) in 96-well plate format on a ﬂuorescence plate reader.
Each well contained approximately 30 μg of mitochondrial protein in a
total volume of 200 μL, coveredwith 150 μL ofmineral oil. Using the res-
piration buffer (250mM sucrose, 15mMKCl, 1 mMEGTA, 5mMMgCl2,
30mMK2HPO4, pH7.4) containing glutamate/malate substratemixture
(both 12.5 mM), state 2 (without ADP) and state 3 respiration (with
1.67 mM ADP) was monitored at 30 °C, as described for iO2. DMOG or
NOG were added to mitochondria at 0–2 mM concentrations 5 min
prior to the measurement. O2 proﬁles were plotted as for NanO2
probe and then OCR values were calculated.2.8. Measurement of medium acidiﬁcation rate by DMOG
Medium acidiﬁcation ratewasmeasured as described for extracellu-
lar acidiﬁcation assay (ECA) [46]. Workingmedium supplementedwith
0, 10 or 20mMHEPES (pH 7.4) and containing 1 μMpH-Xtra probewith
or without DMOGwas added to experimental wells. Plate was immedi-
atelymeasured on theVictor 2 plate reader at 37 °C for 90min in the TR-
Fmodewith excitation/emission at 340/615nm. Two TR-F intensity sig-
nals were measured at delay times of 100 and 300 μs and a measure-
ment window of 30 μs. The emission lifetime τ was calculated as
described for the iO2 and converted in pH values, which were used to
calculate an amount of protons released in the medium in 1 min (H+,
mole/min).
1257A.V. Zhdanov et al. / Biochimica et Biophysica Acta 1847 (2015) 1254–12662.9. ATP measurement
Analysis of total cellular ATP was performed using CellTiter-Glo®
assay, following the manufacturer's protocol. Brieﬂy, cells seeded and
treated as described in Results sectionwere lysedwith CellTiterGlo® re-
agent. After intensive shaking for 2 min, the samples were transferred
intowells of white 96-well plates (Greiner BioOne) and read on aVictor
2 (PerkinElmer) plate reader under standard luminescence settings.
2.10. NADH measurement
In cells, NAD(P)H auto-ﬂuorescence was monitored according to a
modiﬁed method [54]. HCT116 cells were trypsinised, counted, washed
with Krebs buffer supplemented with 2 mM L-Gln, 1 mM pyruvate
10 mM glucose, and loaded into the wells of clear 96-well plate
(5 × 105 cells in 0.1 mL). The ﬂuorescence of samples was monitored
in kinetic mode on the Victor 2 reader at 37 °C with 355 nm excitation
and 460 nm emission ﬁlters. DMOG was added 5 min before the mea-
surement. AntA (10 μM) and FCCP (2 μM) were used as controls to
achieve maximal and minimal ﬂuorescence signal, respectively.
In isolated mitochondria, NAD(P)H levels were monitored similarly
for state 3 respiration driven by glutamate/malate with or without
2 mM NOG.
2.11. Analysis of α-KGDH activity
The activity ofα-KGDHcomplexwas examined by analysing the rate
of increase of NADH ﬂuorescence in the presence of 2.0 mM NAD+,
0.2 mM MgCl2, 0.01 mM CaCl2, 0.12 mM CoA, 2.6 mM L-cysteine, 0–
2 mM α-KG and 0.05 units of commercial α-KGDH in 130 mM HEPES-
Tris buffer (pH 7.4). Analysis was performed on Victor 2 plate reader
at 30 °C (355 nm excitation and 460 nm emission) in the presence of
NOG(2mM)andwithout the drug. The reactionwas initiated by the ad-
dition of CoA and the initial rate of NAD+ reduction was measured.
2.12. Monitoring of cytosolic and mitochondrial pH
HCT116 cells grown on glass bottom dishes were transfected with
mtAlpHi plasmids using Lipofectamine® 2000 and Opti-MEM Imedium
(Invitrogen), as per manufacturer procedure. Loading with ﬂuorescent
sensor BCECF (2.5 μM) was performed for 30 min in Opti-MEM I medi-
um with Ca2+ concentration adjusted to 2 mM. Confocal ﬂuorescence
imaging was conducted on Olympus FV1000 confocal laser scanning
microscope with controlled CO2, humidity and temperature. The
mtAlpHi and BCECF probes were excited at 488 nm (2.5–10% of maxi-
mal laser power) with emission collected at 500–540 nm. Mitochondri-
al H+ gradient (ΔpHm) was dissipated with 2 μM FCCP and increased
with 10 μM oligomycin. Changes in cytosolic pH in cells treated with
DMOGwere compared to that ofmock control (mediumadded). Chang-
es in mitochondrial pH upon addition of FCCP and oligomycin to DMOG
(−) and DMOG (+) cells were cross-compared. In all experiments the
differential interference contrast (DIC) and ﬂuorescence images were
collected kinetically with a 60 × oil immersion objective in two planes
using 0.5 μm step and 20–30 s intervals. The resulting z-stacked images
were analysed using FV1000 Viewer software (Olympus), Excel, Adobe
Photoshop and Illustrator.
2.13. Isolation of RNA and qPCR analysis of gene expression
Total RNA was isolated using RNA isolation kit (Promega), as per
manufacturer protocols. Reverse transcription (RT) reaction was per-
formed using ImProm-II™ RT kit (Promega). Each reaction was per-
formed at 42 °C for 1 h using 2 μg of total denatured DNA-free RNA in
50 μL reaction mixture containing RT buffer, oligo(dT)15 primers,
dNTPs, RNase inhibitor and reverse transcriptase. After heat inactivation
of the enzyme, qPCRwas performed usingQuantiTect SYBR®Green PCRkit (Qiagen, Gaithersburg, MD) on the AB7300 Real‐Time PCR machine
and analysed in 7300 System SDS Software (Applied Biosystems, Life
Technologies). Each sample was analysed in triplicate, both for target
gene and for endogenous control. Averaged Ct values of triplicates
were normalised to endogenous control and used to calculate relative
gene expression values.
2.14. Protein isolation and Western blotting analysis
For total protein isolation, cells were washed with PBS and lysed
with standard RIPA buffer containing phosphatase and protease inhibi-
tors on ice for 15min. Proteins (30 μg per lane) were analysed byWest-
ern blotting as described [55]. Blots were visualised using LAS-3000
Imager (FujiFilm, Japan) and Image Reader LAS-3000 2.2 software.
Quantitative image analysis was performed with ImageJ program.
Histones were extracted from 5–7 × 106 cells grown on 12-well
plates. Cells treated as described in results, were washed with ice-cold
PBS, supplemented with 5 mM sodium butyrate (BA), and lysed on ice
in TEB buffer (PBS, 0.25% Triton X100, 0.02% NaN3, protease inhibitor
cocktail Sigma P2714) for 10 min. Nuclei were precipitated at 600 g,
4 °C for 10 min, washed with TEB, and then histones were acid-
extracted in 125 μL of 0.2 M HCl overnight at 4 °C on rotary shaker. Ex-
tracts were clariﬁed by centrifugation at 2000 g, 4 °C for 10min, protein
concentration was measured by Bradford method and equalised. Sam-
ples were mixed with Laemmli buffer, incubated for 10 min at room
temperature and analysed by Western blotting.
2.15. Modulation of HIF activity and silencing of HIF-1α and HIF-2α gene
expression
To modulate transcriptional activity of HIF-1/2, cells were pre-
incubatedwith FM19G11 (0.5 μMFM19) as described in the Results sec-
tion [56]. Transient knockdown of both HIF-1α and HIF-2α was per-
formed using speciﬁc esiRNA [57] as follows. HCT116 cells were
seeded at 8 × 105 per 6 cm Petri dishes and grown to a 60–70% conﬂu-
ence. Transfectionwith amixture of humanHIF-1A and EPAS1 (HIF-2A)
esiRNA (2.5 μg each) was conducted using a standard Lipofectamine®
2000 protocol for 5 h in OptiMEM medium. EGFP esiRNA was used for
speciﬁcity control. Medium was then replaced by a standard McCoy's
5A medium, and 2 h later cells were trypsinised and seeded as required
for OCR, iO2 andWestern blotting analysis (see above). After 36 h incu-
bation in standard conditions (including loading with NanO2 probe for
iO2 assay), cells were subjected to standard procedures of respiration
analysis or HIF-α stabilisation with DMOG (1 mM, 6 h), followed with
Western blotting.
2.16. Statistical analysis and data presentation
Statistical analysis of the results of 3–5 independent experiments
was performed using the programs SPSS and Excel. p values of ≤0.01
were deemed as statistically signiﬁcant. To ensure the accuracy and ﬁ-
delity of the data, the majority of the experiments with iO2 and ATP
on 96-well plate reader were performed in 3-8 replicates.
The levels of OCR, iO2, NADH and ATP, activity of α-KGDH, cell de-
(re-)oxygenation and medium acidiﬁcation rates were normalised for
total protein content in the samples. ATP levels were also normalised
for those of untreated cells in the medium supplemented with glucose,
glutamine and pyruvate, while NADH autoﬂuorescence — to that in
non-treated cells or mitochondria. Fluorescence intensities on confocal
images (mtAlpHi and BCECF) were analysed in kinetic mode for 40–80
cells in 4 randomly selected ﬁelds of view, and normalised to mock
treated cells. The differences between mean values obtained in plate
reader experiments were evaluated using two-tailed Student t-test
(equal variance was ﬁrst estimated in Levene's test). Analysis of the
Mean values of mtAlpHi, BCECF, Pt-Glc (lifetime) signals obtained on
the microscopes was conducted using Mann–Whitney U-test.
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show phosphorescence lifetime of NanO2 and Pt-Glc as rainbow false
colours; iO2 scale is shown in μM (calculated from corresponding life-
time values).3. Results
3.1. Effect of DMOG on extra- and intracellular acidiﬁcation
First we tested the stability of DMOG in assay media and found that
in the presence of 1 mMDMOG, the H+ concentration progressively in-
creases at a rate of 1.24 × 10−9 mol/min causing gradual acidiﬁcation of
unbuffered medium (Fig. 1A). This can be suppressed by adding 20mM
HEPES to the medium.
Upon translocation to the cytosol and active hydrolysis which re-
leases [H+], DMOG can potentially shift cytosolic pH (Fig. 1B). Using
the cytosolic pH probe BCECF, we analysed this in HCT116 cells and ob-
served no such acidiﬁcation, indicating that H+ are effectively buffered
or extruded from the cells (Fig. 1C). Over the ﬁrst 6 h of DMOG treat-
ment no cytotoxicity was seen and cell appearance, ATP levels and
total protein levels remained unchanged (Supplemental Fig. S1).Table 1
Effect of DMOG on O2 consumption rate in HCT116 cells.
DMOG (mM) 0 0.125
OCR (nM O2/min × mg protein) 5.9 ± 0.5 5.6 ± 0.4
p values (t-test)⁎ N/A N0.05
⁎ Shows differences between DMOG treated and non-treated cells.3.2. DMOG rapidly inhibits mitochondrial respiration in cells
Using actively respiring HCT116 cells as amodel, we tested effects of
DMOG on cellular respiration, by analysing OCR, iO2 and ΔiO2/Δt levels
as assay readouts. OCR analysis demonstrated a concentration-depen-
dent inhibition of respiration in cells, pre-treated with DMOG for 10–
15 min (Table 1, EC50 = 0.65 ± 0.05 mM). These results indicated
that O2 levels in cells treated with DMOGmight be noticeably elevated.
Initial experiments on iO2 performed at 20.9% atmospheric O2 showed
no signiﬁcant differences in basal cell oxygenation for DMOG treated
and control cells, though a trend to higher iO2 was seen in DMOG (+)
cells (Fig. 2A). To better visualise the effect, we treated the cells with
FCCP or EGTAwhich continuously (FCCP) or transiently (EGTA) increase
cell respiration and deoxygenation [49,58] (Figs. 2A-B). We found that
DMOG strongly inhibited respiratory responses to the stimulation.
This concentration-dependent effect was signiﬁcant at a concentration
as low as 0.25mMDMOG (Fig. 2B). To explore this novel effect in detail,
we compared deoxygenation proﬁles in DMOG (+) and DMOG (−)
cells transferred from higher (20.9%) to lower (8%) atmospheric O2. In
conditions of decreased O2 supply, iO2 changes to another steady state
level at a rate which correlates with the OCR [58]. We applied two res-
piration media: with glucose (regular) and galactose (enhanced OCR)0.25 0.5 1 2
4.8 ± 0.4 3.5 ± 0.3 1.6 ± 0.2 0.4 ± 0.1
b0.05 b0.01 b0.001 b0.0001
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Fig. 2. Effects of DMOG on respiration in HCT116 cells. A. Pre-incubation of cells with DMOG (1mM) for 30–40 min abolishes the respiratory response to a mitochondrial uncoupler FCCP
(1.5 μM). Upon FCCP addition the difference in cell oxygenation becomesmore pronounced than at rest (basal iO2 before FCCP addition is shownwith a rectangle). B. Respiratory response
to 5 mM EGTA, a chelator of extracellular Ca2+, is inhibited by DMOG in a concentration-dependent manner. C. DMOG strongly decreases the rate and depth of deoxygenation of cells
transferred from 20.9% to 8% O2 atmosphere. When glucose (Glc) in the medium is replaced with galactose (Gal), deoxygenation is abolished. Quantitative analysis of cell deoxygenation
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(Fig. 2C). Cells deprived of glucose (more glutamine-dependent)
remained oxygenated (80 μM), suggesting a profound decrease of respi-
ration. To examine how fast DMOG acts, we added it to the cells contin-
uously exposed to 8%O2whilemonitoring iO2. By themoment of DMOG
addition cells were deeply and steadily deoxygenated (Fig. 2D). We0
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(1mM, 6 h) to stabilise HIF-α. Cellular content of HIF-α proteinswas analysed byWestern blott
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Most of the known effects of DMOG are mediated by PHD/HIF path-
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1260 A.V. Zhdanov et al. / Biochimica et Biophysica Acta 1847 (2015) 1254–1266siRNA. To start with, we pre-incubated cells for 2 h with FM19G11, a
compound shown to modulate transcriptional activity of HIFs [56],
prior to the addition of DMOG. We found no changes in the effect of
DMOG on the respiratory response to EGTA (Fig. 3A) and proposed
that DMOG acts in HIF-independent manner. To conﬁrm this, we
knocked down both HIF-1α and HIF-2α by transfecting HCT116 cells
with a mixture of speciﬁc esiRNAs, using EGFP esiRNA to transfect con-
trol cells. Western blotting analysis demonstrated that 45–50 h after
transfection the total levels of cellular HIF-1α and HIF-2α proteins de-
creased by 65–75% (Fig. 3B). Silencing of HIF-α did not reduce cell via-
bility, as reported by cellular ATP analysis (Supplemental Fig. S2A).
Neither had it any effect on DMOG-induced decrease in cellular respira-
tion (Fig. 3B and Supplemental Fig. S2B), thus ruling out the involve-
ment of HIFs.
Next,we testedwhether DMOGor its de-esteriﬁed formNOG can di-
rectly inhibit respiration in themitochondria. For this, serial dilutions of
both drugs were added to the mitochondria freshly isolated from rat
liver. After 5 min incubation OCR was measured as described [53]. We
found that NOG at ≥0.5 mM signiﬁcantly inhibited mitochondrial respi-
ration driven by glutamate/malate in the presence of ADP (Figs. 4A–B).
At high NOG concentration (2 mM) the inhibition developed immedi-
ately. No effect of DMOGwas observed in a range of 0–2mMconcentra-
tions tested. These results demonstrated that DMOG: 1) directly inhibits
mitochondrial respiration but 2) has to be de-esteriﬁed to exert its
effect.
In the mitochondria a number of Krebs cycle enzymes might be
inhibited by NOG. Therefore next we set up an in vitro reaction to test
whether NOG can inactivate the α-KGDH complex, which led the list
of potential targets. Using a commercial enzyme (EC 1.2.4.2) we ob-
served no effect of NOG on the initial rate of NAD+ reduction in the
presence of CoA and α-KG (Supplemental Fig. S3).
Finally, to examinehowgeneral the responses to DMOGare,we con-
ducted a selection of the experiments on differentiated neural PC12 cells
(Supplemental Fig. S4). Although PC12 cells were less susceptible to
DMOG treatment, the effects observed in both cell lines were similar,
suggesting that they are not cell-speciﬁc.
3.3. The effect of DMOG on respiration precedes activation of HIF pathways
Results shown in Figs. 2–4 suggested that DMOG/NOG directly in-
hibit mitochondrial respiration, and that the PHD/HIF pathways are
not involved in this inhibition. However, the hierarchy of HIF-
dependent and independent effects of DMOG on cell metabolism
remained to be clariﬁed. Therefore, bearing in mind that respiratory re-
sponse to DMOG was almost immediate (Fig. 2D, Supplemental
Fig. S2B), we examined the dynamics of HIF signalling.Western blotting
analysis revealed measurable increase in HIF-1α and HIF-2α levels al-
ready 30 min after DMOG addition (Fig. 5A) and further elevation due
to inhibition of PHD proteins (see also the kinetics of HIF-α stabilisation0
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onstrate SD. Asterisks show signiﬁcant difference from mock treated mitochondria (p b 0.01).and HIF-dependent gene expression in HCT116 cells under 1% hypoxia
(Supplemental Fig. S5)). Concordant to the classical scenario, qPCR anal-
ysis revealed a lag in expression of HIF-target genes, with an onset at
0.5–2 h after DMOG addition (Fig. 5B). Increases in the levels of speciﬁc
proteins associated with the ﬁnal stage in the HIF cascade, developed
even slower (Figs. 5A, C). Together, this clearly shows that inhibition
of respiration occurs well ahead of HIF-dependent events, and early
changes in cell metabolism, typical for DMOG, are attributed to its direct
effect on mitochondrial activity.
3.4. Changes in cell bioenergetics induced by DMOG
A pronounced inhibition of respiration by DMOG suggested a reduc-
tion in mitochondrial ATP ﬂux in treated cells, which should increase
their glycolytic component in ATP pool. Therefore cells deprived of glu-
cose were expected to be vulnerable to DMOG treatment, particularly
when they had to rely on glutamine as themajor source of ATP. Recently
we reported on DMOG-dependent decrease in ATP in PC12 cells, de-
prived of glucose [55]. To further explore this effect, we analysed the dy-
namics of ATP in HCT116 cells treated with DMOG under deprivation of
metabolic substrates. In the presence of glucose, glutamine and pyru-
vate, ATP levels remained steady for at least 4 h of treatment (Fig. 6A).
Without glutamine, ATP did not change for 2 h and then decreased.
Themost dramatic changeswere observed in cells without glucose, par-
ticularly with glutamine being the only substrate, where ATP levels de-
creased substantially already in 30 min after DMOG addition and
dropped to almost zero in 4 h. It is worthy to note that in mock-
treated cells ATP remained unchanged in all the media (not shown).
We also inhibited glycolysis with STF-31 (GLUT1 inhibitor) [59] or
lonidamine (HK2 inhibitor) [60] and monitored changes in cellular
ATPover a period of 2 h. In the presence of these compounds, particular-
ly lonidamine, ATP levels were strongly affected by DMOG (Fig. 6A).
This demonstrates a therapeutic potential of double treatment of cancer
cells with DMOG, which inhibits OxPhos and drugs, which selectively
target glycolysis.
OxPhos efﬁciency is determined by proton motive force (PMF) gen-
erated mainly by the electron transport chain (ETC) from reducing
equivalents of the Krebs cycle NADH and FADH2. We found signiﬁcant
decrease in cell autoﬂuorescence at 355 nm/450 nm (ex./em.) upon
20 min treatment with DMOG, indicating that cellular NADH pool was
substantially depleted (Fig. 6B). In isolated mitochondria during stage
3 respiration driven by glutamate/malate, NOG reduced NADH levels
by 15%, suggesting an inhibition of NADH production in the mitochon-
drial matrix (not shown). PMF combines energy of ion gradients gener-
ated across the inner mitochondrial membrane, including H+ gradient
(ΔpHm). To examine the effects of DMOG on ΔpHm we applied
oligomycin, which inhibits H+ utilisation by F1Fo ATP synthase, causing
a rapid alkalinisation of themitochondrial matrix in cells with function-
ally active Krebs cycle and ETC. Using a mitochondria targeting pH-30
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1262 A.V. Zhdanov et al. / Biochimica et Biophysica Acta 1847 (2015) 1254–1266sensitive probemtAlpHi, we found that in cells shortly pre-treatedwith
DMOG the response to oligomycin was reduced, pointing to a decrease
in the capacity of mitochondria to generate ΔpH (Fig. 6C). Overall these
data suggested a decreased efﬁciency of the Krebs cycle, though direct
effects of DMOG on the ETC cannot be ruled out.
3.5. HIF-independent effect of DMOG on histone K16H4 acetylation
Inhibition of the Krebs cycle by DMOGmay affect cellular processes
requiringmitochondrialmetabolites, including pyruvate, citrate, NAD+/
NADHand acetyl-CoA. All of themare involved in the regulation of chro-
matin opening via acetylation of histones (e.g., lysine 16 of histone H4)
[61]. To test whether DMOG can act as a HIF-independent epigenetic
modulator, the levels of H4K16ac were examined in HCT116 cells pre-
incubated for 2 h with FM19G11 and then exposed to 20.9% and 5% at-
mospheric O2 for 3 h, with or without DMOG. The levels of iO2 were
monitored during the experiment (Figs. 2A and 3A showbasal iO2 levels
at 20.9%, Fig. 7A — at 5% atmospheric O2).
An elevation of HIF-1α and HIF-2α levels in normoxic cells treated
with DMOG conﬁrmed an inhibitory effect of the compound on PHD
proteins (Fig. 7B). In both hypoxic samples HIF-1α and HIF-2α levels
were equally increased. Analysis of H4K16ac content revealed an inhib-
itory effect of DMOGonhistone acetylation. A decrease in H4K16ac, par-
ticularly pronounced in cells exposed to 5% O2, was clearly HIF-
independent, since a prominent increase in HIF-α levels observed in
hypoxic cells without DMOG did not affect H4K16 acetylation.
H4K16ac levels depend on the availability of acetyl-CoA, which is
regulated by numerous factors, including activity of acetyl-CoA carbox-
ylase (ACC) [73]. The observed increase in phosphorylation of ACC at Ser
79, known to inhibit the enzyme activity in AMPK-dependent manner,
suggests that ACC does not contribute to a decrease in H4K16ac in our
model (Fig. 7B).
3.6. Effect of DMOG on respiration and iO2 of 3D tissue models
Since 2D cell cultures have little resemblance with in vivo condi-
tions, we examined the effect of DMOG in 3Dmodels comprisingmulti-
cellular spheroids and excised animal tissue. Spheroids were produced
by culturing HCT116 cells for three days in Lipidure-Coat U-bottom
96-well plate. They were loaded with NanO2 probe, which allowed
high resolution phosphorescence lifetime imaging of O2 on the surface0
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Fig. 7.A decrease of H4 lysine 16 acetylation in cells treatedwith DMOG. A. Deoxygenation proﬁ
In thepresence of DMOG(1mM) iO2 remains higher than innon-treated cells: after 1 h incubati
blotting analysis demonstrates a decrease in H4K16ac in cells treated with DMOG for 3 h, p
normoxia and hypoxia conﬁrms DMOG activity. The levels of phosphorylated ACC (Ser79) are
prior to the treatment with DMOG. N = 3; error bars demonstrate SD.and in the core of the spheroid. Tomaximise the effects of DMOG, spher-
oidswere deprived of glucose for 2 h prior to themicroscopy evaluation,
which was performed at 20.9% atmospheric O2. Individual spheroids
were imaged in 15–20 confocal planesmeasuring probe lifetime signals,
then DMOG was applied, and after 15 min imaging was repeated. Con-
trol spheroids of similar size were imaged twice without addition of
DMOG (not shown). After DMOG addition we observed a noticeable in-
crease in iO2 levels in the core regions of spheroids (Figs. 8A–D) as a re-
sult of rapid inhibition of respiration. This suggests that in conditions of
limited O2 availability in tissue (e.g., upon inﬂammation) [63], DMOG
treatment can rapidly increase iO2 and relieve hypoxic stress.
This was tested on a common model of colitis induced in mice by
systemic administration of DSS [64]. To induce noticeable inﬂammation
but avoid degradation of colon epithelium, a short 4-day course of DSS
was selected. In a similar study of DSS-induced (5-day) murine colitis,
co-administration of DMOGwas seen to increase HIF-1 andNF-κB activ-
ity, ameliorate the severity of disease and improve the repair and regen-
eration of colon epithelium [20]. After3 h incubation of the inﬂamed
distal colon with Pt-Glc probe ex vivo, we performed microscopy and
observed intense staining of epithelial cells (Fig. 8E). Oxygenation of dif-
ferent parts of the tissue varied, being in the range of 10–35 μM O2 for
~90% of cells at 20.9% atmospheric O2. Without treatment, these values
remained unchanged during 2–3 h of the imaging. Treatment with
DMOG (1 mM) caused a substantial shift of the histogram of oxygena-
tion towards higher iO2 values (Fig. 8E). The average iO2 in the epitheli-
um increased from 12.7 μM to 16.9 μM in 20–25 min after addition of
DMOG. In agreement, the fraction of cells with O2 levels higher than
15 μM increased from 38% to 64%, indicating an overall elevation of in-
crease in tissue oxygenation due to the inhibition of mitochondrial res-
piration. These results suggested that in vivo DMOG administration can
increase O2 availability in inﬂamed colon tissue, and improved tissue
oxygenation may contribute to the therapeutic effects of DMOG
shown previously in mice with DSS-induced colitis [20,63].
4. Discussion
DMOG is a common structural analogue ofα-KG, targeting primarily
α-KG-dependent enzymes. The effects of DMOG and NOG are described
in numerous publications, with the studiesmainly focused on inhibition
of PHD and activation of HIF cascade. Scarce data on other effects
exerted by DMOG (e.g., modulation of NF-κB, TNF-α, AMPK or histone0
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Fig. 8. Rapid increase of iO2 levels in 3Dmodels upon treatment with DMOG. A. iO2 distribution in a spheroid formed from HCT116 cells and continuously stained with NanO2 probe. 15
confocal planeswith a 5 μmstep are taken before and 15min after application of 1mMDMOG (2min is required to image a single plane). Colour changes demonstrate increased iO2 levels
by DMOG. Top left panel shows a DIC image of the spheroid. B. Average iO2 in 3 randomly selected ROI (highlighted in A) before and after the treatment. C. A shift in probe lifetime dis-
tribution histogram (averaged for 15 confocal planes) shows an increase in iO2 levels, in contrast to control sample (mock, Krebs buffer is added). Average iO2 before (75 μM) and after
(108 μM) addition of DMOG is shown. D. Calculated for the cells with themost representative O2 levels (N50% frequency on the histogram), the range of oxygenation changes upon treat-
ment with DMOG from approximately 50-100 μM to 80-140 μM. Time slots for imaging and treatment with DMOG are shown in minutes. E. 3D reconstruction of iO2 levels in colon ep-
ithelium of mice with DSS-induced colitis, imaged using Pt-Glc probe (left panel). Tissue staining with 20 μMprobewas performed ex vivo for 3 h at 37 °C. 12 confocal planes with a 5 μm
step are taken before (resting conditions) and 20 min after application of DMOG (1 mM). DIC image (top right) exempliﬁes structure of the colon epithelium. A shift in probe lifetime
distribution histogram (averaged for 10 confocal planes) shows an increase in tissue oxygenation. In control sample (mock, Krebs buffer is added) iO2 levels do not change. Average
iO2 before (12.7 μM) and after (16.9 μM) addition of DMOG is shown. The proportion of cells containing more than 15 μM O2 is highlighted in light green. Blue line demonstrates a rela-
tionship between iO2 and probe lifetime (τ). Scale bars on the images represents 100 μm. Error bars show SEM. Asterisk indicates signiﬁcant difference (p b 0.01).
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pound [20–27]. Inhibition of O2 consumption by cells treated with
DMOG has been reported previously [37–39]. However this effect was
described as a rather slow process (6–48 h of treatment), attributed to
the events taking place downstream of protein hydroxylation by PHD
and FIH, rather than to a direct inhibition of themitochondrial enzymes.
These events include the inhibition of pyruvate metabolism via HIF-
dependent increase in transcription of PDK1 and PDK3 [65–67], de-
crease in the Krebs cycle enzyme subunit SDHB [68] or increased levels
of complex I inhibitor NDUFA4L2 [69].
We demonstrate for the ﬁrst time that DMOG can in minutes de-
crease cellular respiration by directly inhibiting mitochondrial function
of intact cells (Figs. 2–4, Table 1). This can be observed in a range of
DMOG concentrations commonly used to inhibit PHD (0.1–1 mM).
We show that 1 mM DMOG reduces basal respiration and respiratory
responses of HCT116 cells to sustained mitochondrial uncoupling withFCCP, and transient cytosolic Na+ inﬂux triggered by chelation of extra-
cellular Ca2+ with EGTA [49,58]. Under moderate hypoxia (e.g., 8% O2)
cells treated with DMOG cannot become hypoxic as they normally do
due to active O2 consumption (Fig. 2C). Moreover, O2 levels in continu-
ously hypoxic cells rapidly increase as soon as respiration is inhibited
with DMOG (Fig. 2D). Such a reduction in basal respiration and spare re-
spiratory capacity is associated with a decrease in NADH production
and, subsequently, in ETC activity (most probably, NADH-driven com-
plex I) (Figs. 6B–C). Rapid effects of DMOGwere seen in all models test-
ed, including 2D and 3D cell cultures, rat liver mitochondria and mouse
colon tissue. Observed variability of the responses to DMOGmost prob-
ably reﬂects differences in the complexity of models (2D, 3D), and im-
portance of glutamine/α-KG metabolism for a particular type of cells
(Figs. 2 and 8A–D).
Slow hydrolysis of DMOG causes progressive acidiﬁcation of media
(Fig. 1). Inside the cells this process is accelerated by esterases. As a
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ity, accumulates in the cells. Although NOG is a dicarboxylic acid, it does
not affect cytosolic pH, at least during 50 min of treatment with DMOG.
Cellular ATP levels also remain unchanged, as long as cells are fed on
glucose. However, when HCT116 cells are limited in glucose and have
to rely on OxPhos, ATP levels are greatly reduced by DMOG (Fig. 6A).
This suggests that cancer cells addicted to glutamine as a source of α-
KG can be particularly sensitive to DMOG, in conditions when glucose
metabolism is inhibited. Such vulnerability under energy stress induced
by DMOG treatment makes this compound an attractive candidate for
metabolic targeting of cancer cells. This is particularly important, since
the observed inhibition of respiration in HCT116 cells treated with
DMOG resembles that in FH and SDH deﬁcient cells. Pro-oncogenic mu-
tations in these Krebs cycle enzymes cause accumulation of fumarate
and succinate, impairment of respiration and increase in iO2, swelling
of mitochondria and disruption of cristae, as shown for UOK262 cells
[70], ‘metabolic’ stabilisation of HIF-α and specialised metabolism
[71]. Although activation of HIF pathways enhances adaptability of
these cells to hypoxia, their susceptibility to speciﬁc treatment increases
[16], and therefore compounds mimicking α-KG might help selecting
suitable therapeutic strategies.
Although an increase in glycolytic ﬂux is undoubted (Fig. 6A), an ob-
served depletion of cellular NADH pool (Fig. 6B) may affect glycolytic
activity. Indeed, pyruvate consumption by mitochondria in cells treated
with DMOG decreases, and most of pyruvate produced via glycolysis
should be converted to lactate and released by cells. In turn, pyruvate-
to-lactate conversion conducted by LDH is coupled with NADH oxida-
tion, and without sufﬁcient NADH production this step may become a
bottleneck of the glycolytic cascade. Activity of LDH is also regulated
by pyruvate (positively) and iO2 (negatively), therefore estimation of
the overall efﬁciency of glucose metabolism upon DMOG treatment is
challenging and requires additional analysis. Another consequence of
the increase in iO2 upon DMOG treatment is worthy of mentioning. An
escape fromdeep hypoxia (Figs. 2C–D) can activate ROS production.De-
pending on the conditions (the rate of re-oxygenation, the efﬁciency of
antioxidant machinery of the cell), this side effect can contribute to
PHD-dependent stabilisation of HIF-α, or trigger cell death. Ironically,
by elevating cell oxygenation under hypoxia, DMOG also increases O2
availability for FIH and PHD proteins, which down-regulate HIF
pathways.
Independence of the observed effects fromHIF pathway is an impor-
tant feature. Western blotting and qPCR analyses show that HIF-α sub-
units are rapidly stabilised in the presence of 1 mM DMOG (which is
similar to HIF-α stabilisation under hypoxia (Supplemental Fig. S5, see
also [72])). However it takes hours for the levels of HIF-targeted
mRNA and particularly proteins to be changed (Fig. 5). Almost instanta-
neous inhibition of respiration by DMOG (Fig. 2D) suggests that it pre-
cedes HIF-dependent alterations in cell metabolism. In agreement, a
pre-treatment of cells with a modulator of HIF signalling FM19G11
and particularly double knockdown of HIF-1α/HIF-2α do not alter re-
spiratory response to DMOG (Fig. 3, Supplemental Fig. S2). Finally, the
contribution of HIF and other cytosolic factors to the rapid effects of
DMOG can be ruled out by our data on direct inhibition ofmitochondrial
respiration by NOG (Figs. 4A–B). The results obtained on isolated mito-
chondria also demonstrate that NOG, but not DMOG is an ‘active com-
pound’, inhibiting respiration. One can see though that NOG has to
accumulate in cytosol to ≥ 0.5 mM to cause detectable inhibitory effect.
Intriguingly, NOG exerted no direct effect on α-KGDH activity in vitro
(Supplemental Fig. S3). Additional studies are required to identify
exact targets and mechanisms of mitochondrial inhibition by DMOG/
NOG.
HIF-independent decrease in H4K16ac in DMOG-treated cells is very
interesting, though its explanation is challenging (Fig. 7). Indeed, the
level of histone acetylation depends on the availability of acetyl-CoA
and the activity of acetyltransferases and deacetylases, as well as acetyl-
CoA synthase, ACC, pyruvate dehydrogenases, ATP citrate lyase andother players [62,73–76]. Thus, ACC can deplete acetyl-CoA pool required
for the efﬁcient histone acetylation. However, DMOG has been shown to
activate AMPK, which inhibits ACC function via phosphorylation. Indeed,
an elevated Ser79 phosphorylation observed upon DMOG treatment
(Fig. 7B) indicates that ACC is hardly implicated in the effect of DMOG
on H4K16 acetylation. In contrast, an inhibition of the Krebs cycle in the
presence of DMOG suggests that concomitants changes in mitochondrial
citrate, acetyl-CoA and NADH production can affect H4K16ac levels.
Among other enzymes, NAD+-dependent histone deacetylases of SIRT
family seemparticularly attractive contributors to the shift inH4K16 acet-
ylation state, because an observed increases in cellular NAD+/NADH ratio
can burst histone deacetylation upon DMOG treatment. Further analysis
is required to elucidate the mechanism(s) of this effect.
It is postulated that tissue hypoxia and inﬂammation are mutually
regulated [77]. Hypoxia triggers vascular leakage and edema, activates
pro-inﬂammatory signalling and inﬁltration, and stimulates expression
of toll-like receptors and apoptosis, thus promoting inﬂammation. In
turn, inﬂammation obstructs O2 delivery to the core of inﬂamed tissue,
while all energy-demanding immunological processes activate O2 con-
sumption, causing deep local hypoxia. Cytochrome c oxidase retains
its half-maximal activity even at 0.1-0.5 μM O2 [78,79] and can reduce
iO2 to the levels insufﬁcient for many other cellular oxidoreductases.
An inhibition of O2-dependent cellular processes imposes large func-
tional stress on the inﬂamed tissue. The reduction of the Krebs cycle ac-
tivity and mitochondrial respiration by DMOG increases O2 availability
and modulates levels of mitochondrial metabolites essential for the
maintenance of redox balance and vital cellular processes. In this regard,
DMOG can contribute to improved cell survival and tissue restoration
reported in vivo in the DSS-induced colitis model (Fig. 8E) [20]. Particu-
larly relevant is a substantially decreased H4K16 acetylation in cells
treated with DMOG under hypoxia, because associated chromatin re-
modelling can modulate HIF and NF-kB speciﬁc transcription, both
shown to play a pivotal role in hypoxia-associated inﬂammation [20,
63,80]. An interplay between a decrease in NADH, reduction of OxPhos,
activation of glycolysis and increase in O2 levels observed in the in-
ﬂamed tissue upon treatment with DMOG, is still to be understood.
Nonetheless, our data on the changes in O2 availability induced by
DMOG helps to reﬁne the understanding of themechanisms underlying
pathogenesis and potential treatment of inﬂammatory bowel disease.
Overall, we believe that direct inhibition ofmitochondrial activity by
DMOG/NOG causes rapid re-arrangement of cell metabolism, preceding
activation ofHIF-dependent processes. This knowledge broadens attrac-
tive perspectives for application of DMOG and other synthetic ana-
logues of α-KG and the oncometabolites fumarate, succinate and (R)-
2-hydroxyglutarate in the studies on physiological aspects of hypoxia,
mitochondrial dysfunction and metabolic targeting of tumour.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbabio.2015.06.016.
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